ReviewSchizophrenia research2008
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
Review in Schizophrenia research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.Dialogues in clinical neuroscience · 2026Pooled it
- Pharmacological interventions for prevention of weight gain in people with schizophrenia.The Cochrane database of systematic reviews · 2022Pooled it
- Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2015Pooled it
- Effect of Supplementation with Probiotics in Patients with Schizophrenia: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.Foods (Basel, Switzerland) · 2025Review
- Elevated serum IL-17 A and CCL20 levels as potential biomarkers in major psychotic disorders: a case-control study.BMC psychiatry · 2024Article
- Article
- High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects.Translational psychiatry · 2024Article
- Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.Psychiatry research · 2024Article
- The Pathologic Roles and Therapeutic Implications of Ghrelin/GHSR System in Mental Disorders.Depression and anxiety · 2024Review
- Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations.Current psychiatry reports · 2023Review
- Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: III. Biology.Schizophrenia bulletin · 2023Article
- Clinical review: Guide to pharmacological management in pediatric obesity medicine.Obesity pillars · 2023Review
- Mechanism and treatments of antipsychotic-induced weight gain.International journal of obesity (2005) · 2023Review
- Selective 5-HTPharmaceuticals (Basel, Switzerland) · 2023Article
- Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome.Journal of personalized medicine · 2022Article
- Association of higher plasma leptin levels with HOMA-IR index, high sensitivity C-reactive protein and glycolipid metabolism in patients with chronic schizophrenia: A multi-center cross-sectional study.Frontiers in psychiatry · 2022Article
- Ghrelin mediated regulation of neurosynaptic transmitters in depressive disorders.Current research in pharmacology and drug discovery · 2022Review
- Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: State-of-the-art and future perspectives.World journal of psychiatry · 2021Review
- Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.Behavioural brain research · 2021Review
- The Role of the Central and the Peripheral Neuropeptides in Weight Gain and Metabolic Changes Related to Olanzapine.Psychiatry and clinical psychopharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMany adverse effects of atypical antipsychotic treatment are associated with antagonism of monoamine receptors; however, data indicate that important metabolic effects, such as hypertriglyceridemia and impairment in glucose/insulin homeostasis, may not be related to these mechanisms, leading investigators to explore alternative hypotheses. Promising candidates include a possible impact of antipsychotics on peptide hormonal regulators of metabolic control such as leptin, ghrelin, and adiponectin. The purpose of this review is to summarize recent data on changes in these hormones during atypical antipsychotic treatment.
methodsA Medline search was performed for papers published from January 1999 to January 2007 using key words antipsychotic, atypical antipsychotic, and individual atypical antipsychotic drug names cross-referenced with leptin, ghrelin, and adiponectin.
resultsThe bulk of the published work focused on changes in body weight and serum leptin, with far less data on ghrelin, and adiponectin, and nonweight metabolic changes. Leptin changes were directly related to a medication's weight gain liability, with no added antipsychotic effects on leptin signaling. Conflicting results emerged for the other markers, but all three long-term studies on ghrelin showed increased levels in patients on atypical antipsychotics with weight gain liabilities.
conclusionsLeptin increases during antipsychotic treatment are a result of weight gain rather than a direct impact of atypical antipsychotics on leptin physiology. Preliminary long-term data show increased ghrelin levels, but this finding must be replicated. The association with antipsychotic effects on glucose and lipid metabolism and these hormones remains virtually unstudied. Future research should indicate whether ghrelin and other peptide hormones may be useful predictors of weight gain or metabolic changes in patients on antipsychotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.